NuScale Power Is Still Under $13. Here's Whether Long-Term Investors Should Pounce.

NuScale Power is the only U.S. nuclear company with an NRC-approved SMR design, but it is still pre-revenue at scale and posted just $565,000 of Q1 revenue versus a $57 million operating loss. The company has two major projects underway — a 462-megawatt Romanian plant and 6 GW for TVA via ENTRA1 — yet neither is expected to finish before 2030. With roughly $1 billion in liquidity, the article argues the $4.5 billion market cap looks stretched until NuScale secures a firm sale.

Analysis

SMR’s key issue is not technology acceptance but capital efficiency: the market is still pricing a long-dated option as if it were a near-term utility-scale cash flow story. That mismatch creates a fragile equity setup, because any delay in first revenue forces repeated reliance on the capital markets while the story’s fundamental proof point remains years away. In a rate-sensitive tape, long-duration pre-revenue assets typically de-rate hardest when investors rotate from narrative to financing risk.

The second-order winner is not NuScale itself but adjacent names that can monetize nuclear/AI enthusiasm without carrying the same execution burden. OKLO and BE may retain a valuation premium because they are still “optionality” vehicles, but the relative trade now favors the company with the clearest commercialization path and less permitting overhang. More broadly, the article underscores that AI-driven power demand is boosting the entire clean-baseload basket, yet the market is starting to distinguish between approved design, contracted backlog, and actual megawatts delivered.

The main contrarian miss is that approval plus pipeline can still be worth a lot if the first project reaches a financing close; the market is likely underestimating how quickly sentiment can rerate on even one binding EPC/utility contract. But until that happens, each quarter of burn without conversion increases dilution probability and compresses the terminal equity value. The risk/reward is therefore asymmetric against the stock: upside requires a binary catalyst, while downside can unfold gradually through cash burn, delayed milestones, and multiple compression.

Key Decisions for Investors

• Underweight/short SMR into strength over the next 1-3 months; thesis is valuation compression from pre-revenue burn and delayed commercialization. Risk: a binding project financing or utility FID could trigger a sharp squeeze.
• Pair trade: long BE / short SMR for a 3-6 month relative-value expression on nearer-term monetization versus longer-dated project risk. Risk/reward favors BE if power-demand enthusiasm persists but the market continues to penalize execution lag.
• Buy OKLO call spreads 6-12 months out only as a higher-beta AI-power optionality trade; keep sizing small. This captures upside from sector rerating while capping premium if nuclear sentiment cools.
• Avoid owning SMR outright until there is evidence of first firm revenue conversion or a visible project financing milestone; the negative carry from dilution risk outweighs the narrative premium at current levels.
• If already long SMR, hedge with short-dated puts around earnings or project-update windows; the stock’s most likely inflection points are catalyst-driven, and downside can gap on timeline slippage.